What the Danish Study Discovered

In their investigation, Schmeling et al. examined the rates of suspected vaccine adverse events (SVAEs) linked to different batches of Pfizer's mRNA vaccine administered in Denmark between December 27, 2020, and January 11, 2022. They analyzed data from the Danish Medical Agency, focusing on the severity and batch details of reported SVAEs.

During the study, 7.8 million doses were given to 3.7 million individuals from 52 distinct batches, ranging from 2,340 to 814,320 doses each. A total of 43,496 SVAEs were reported across 13,635 individuals, resulting in an average of 3.2 SVAEs per person, with 75% classified as non-serious, 24% as serious, and 1% as fatal.

Surprisingly, the incidence of SVAEs per 1,000 doses exhibited significant variance across different batches, with a median of 2.32 SVAEs and an interquartile range of 0.09 to 3.59. This indicates that specific vaccine batches could lead to as few as 0.1 to as many as 4 SVAEs per 1,000 doses, highlighting a concerning variation in safety profiles.

Diving deeper into the data revealed three distinct trend lines:

1. High-Risk Batch (Blue): Only 4.2% of doses but accounted for 71% of SVAEs (including 28% serious and 47% fatal).
2. Moderate Risk Batch (Green): Comprising 64% of doses, contributing to 29% of SVAEs (with 72% serious and 52% fatal).
3. Low-Risk Batch (Yellow): Representing 32% of doses but only 0.4% of SVAEs (including 1% serious and 0.9% fatal).

A statistically significant relationship was identified between the rate of SVAEs and batch size, revealing that smaller batches were associated with higher adverse event rates.

Quality Control Measures in Vaccine Production

In Denmark and other EU/EEA nations, a minimum of 15 doses from each batch must undergo testing by an independent lab, following the Official Control Authority Batch Release (OCABR) guidelines. This ensures that all distributed vaccines meet necessary quality standards.

Quality control checks for mRNA vaccines include evaluations of:

• Appearance: Checking for visible or sub-visible particles.
• Identity: Verifying mRNA content and lipid nanoparticle components.
• Potency: Assessing concentrations of mRNA and lipid nanoparticles.
• Integrity: Evaluating the stability and purity of mRNA.

These guidelines aim to account for the inherent variability present in biological products. Unlike traditional drugs, vaccines are derived from living organisms, which can introduce complexities and risks of contamination.

A significant limitation of this quality control system is that it assesses batches rather than individual doses. Testing every dose is impractical, as once a vial is opened, it can no longer be distributed. As highlighted in a 2021 paper in the journal Vaccine, the assumption that all vials within a batch are identical may overlook variances caused by manufacturing and handling.

Historical Context of Vaccine Recalls

Defective vials may slip through quality control, leading to potential harm. Historical examples include:

• In 2013, 33 batches of insulin pens were recalled due to significant insulin level deviations, with minimal reported adverse events.
• The CDC has documented several vaccine batch recalls, including the polio vaccine from 1995 to 1963 and the rotavirus vaccine from 1998 to 1999.
• In 2021, contamination was detected in 39 vials of Moderna's mRNA Covid vaccine in Japan, resulting in the precautionary disposal of over a million doses.

Despite these instances, batch-to-batch variability does not always lead to adverse outcomes. A 2021 report revealed that early batches of Pfizer's mRNA vaccine contained truncated mRNA, potentially affecting potency but lacking definitive evidence of harm.

Exploring the Implications of Batch Variability

While the case for batch-dependent vaccine safety lacks robust support, it raises crucial questions. The findings rely on voluntary reporting systems, which can suffer from underreporting and bias. As Schmeling et al. noted, these observations should be viewed as hypothesis-generating rather than definitive proof of causation.

The relationship between smaller batch sizes and higher rates of SVAEs remains unexplained, casting doubt on the validity of these findings. Possible explanations could include lapses in manufacturing diligence for smaller batches or a prioritization of quality control for larger batches.

Engaging in scientific discussions about vaccine quality control is essential for public health, and researchers like Yu et al. have proposed advanced methods, such as water proton nuclear magnetic resonance (wNMR), to analyze vaccine vials without unsealing them. This innovative technology has already shown promise in detecting variations within vaccine batches.

In conclusion, while vaccine quality control is not infallible, the scientific community continues to address these challenges to enhance public health outcomes. It's vital to approach these discussions with a balanced perspective, recognizing the importance of vaccines while striving for continuous improvement in safety protocols.

Thank you for reading! If you found this discussion enlightening, consider subscribing to my Medium email list for more insights. Your support is greatly appreciated.